Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1-Reference-Cited by-同舟云学术

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

Published:2011-12 Issue:6 Volume:54 Page:1956-1965
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Nettles Richard E.,Gao Min,Bifano Marc,Chung Ellen,Persson Anna,Marbury Thomas C.,Goldwater Ronald,DeMicco Michael P.,Rodriguez-Torres Maribel,Vutikullird Apinya,Fuentes Ernesto,Lawitz Eric,Lopez-Talavera Juan Carlos,Grasela Dennis M.

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.24609/fullpdf

Reference14 articles.

1. Diagnosis, management, and treatment of hepatitis C: an update;Ghany;HEPATOLOGY,2009

2. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors;Kwong;Curr Opin Pharmacol,2008

3. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial;Kwo;Lancet,2010

4. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 ADVANCE study;Jacobson;HEPATOLOGY,2010

5. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system;Fridell;Antimicrob Agents Chemother,2010

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells;Biomedicine & Pharmacotherapy;2024-10

2. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy;Current Drug Metabolism;2024-02

3. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03

4. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation;Molecules and Cells;2021-09-30

5. Bioequivalence of daclatasvir hydrochloride tablets in healthy Chinese subjects;Int. Journal of Clinical Pharmacology and Therapeutics;2021-08-01